|
Video: What is a Stock Split?
|
|
BridgeBio Pharma is a biopharmaceutical company to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. Co.'s pipeline includes: Acoramidis (Eidos), which is an oral small molecule Transthyretin (TTR) stabilizer for the treatment of TTR amyloidosis; Low-dose Infigratinib, which is an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of achondroplasia; BBP-418, which is a small molecule substrate replacement therapy for the treatment of Limb Girdle Muscular Dystrophy Type 2I; and BBP-812, which is an adeno-associated virus gene therapy for the treatment of Canavan Disease. According to our BridgeBio Pharma stock split history records, BridgeBio Pharma has had 0 splits. | |
|
BridgeBio Pharma (BBIO) has 0 splits in our BridgeBio Pharma stock split history database.
Looking at the BridgeBio Pharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BridgeBio Pharma shares, starting with a $10,000 purchase of BBIO, presented on a split-history-adjusted basis factoring in the complete BridgeBio Pharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/28/2019 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$26.97 |
|
End price/share: |
$30.92 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
14.65% |
|
Average Annual Total Return: |
2.92% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$11,466.13 |
|
Years: |
4.75 |
|
|
|
|
|